Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.
Our 225-page report provides 192 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this nascent pharmaceutical market.
Forecasts from 2015-2025 and other analyses show you commercial prospects Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis), product profiles and commercial developments. Read the full transcripts of one exclusive expert opinion interview from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales, including: • Dr Katarzyna Nej-Wolosiak, Medical Science Lead, SOTIO
See revenue forecasts for the most promising products in development How will leading prostate cancer drugs and devices perform to 2025 at world level? Our study forecasts sales of 9 leading drugs, including: • Zytiga • Xtandi • Xofigo • Lupron • Zoladex • Taxotere • Provenge
Furthermore, this report will show your revenue forecast to 2025 for 5 leading procedures: • Brachytherapy • Radical prostatectomy • External beam radiation • Cryotherapy • HIFU
Discover how high revenues can go. Our analysis also breaks the main world forecast into geographical markets.
What are the prospects in the leading regions and countries? In addition to analyses of the overall world market, you discover individual revenue forecasts to 2025 for: • US • EU5 (Germany, France, Italy, Spain and the UK) • Japan • South Korea • India • China • Brazil • Russia • Mexico • Rest of the World
There will be growth in both developed and developing pharmaceutical markets. Our analyses show that the “Rest of the world” market will achieve high revenue growth by 2025.
Leading companies and potential for market growth Overall, world revenue for prostate cancer therapies will reach $8.3bn in 2015, our work forecasts. We predict strong revenue growth through to 2025. Market entry of novel therapies, an increasing patient population and diagnostic rates will result in a significant increase in sales over the next decade.
See Visiongain’s analysis of 7 leading companies, including these: • Johnson & Johnson • AstraZeneca • Varian Medical Systems • Elekta • Sanofi • AbbVie • Theragenics
A company profile gives you the following information where available: • Historical revenues • Discussion of a company’s activities and outlook, including promising pipeline products • Recent financial results • Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
Research and development – assess innovation, trends and possibilities What about R&D – the pipeline for new drugs? You see trends for these areas and technologies: • Immunotherapies • Gene therapies • Androgen Receptor Antagonists
New prostate cancer drugs are in great demand to allow patients more personalised treatment plans. Our work explains, discussing many issues.
How the Prostate Cancer Therapeutics Market Forecast 2015-2025: Opportunities for Leading Companies report helps you In summary, our 225 page report gives you the following knowledge: • Market forecasts to 2025 for the prostate cancer drugs and devices markets – find out what the next decade holds for both markets, assessing annual growth rates and market shares. • Revenue forecasts to 2025 for the leading national markets • Predicted revenues of 9 leading drugs to 2025 – see potentials of top products • Assessment of 7 leading companies – hear about products, results and strategies including pipeline analysis and recent developments • Review of R&D pipelines – investigate developmental trends and progress • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market • View interviews with authorities
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the prostate cancer therapeutics market and leading the leading companies. You find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 The Prostate Cancer Therapeutics Market Overview 1.2 Prostate Cancer Therapeutics Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Key Questions Answered by This Analytical Report 1.6 Who is This Report For? 1.7 Methodology 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Reports 1.10 About Visiongain
2. An Introduction to Cancer 2.1 What is Cancer? 2.2 Phenotypic Characteristics of Cancer Cells 2.2.1 Uncontrollable Growth 2.2.2 Loss of Functioning Apoptotic Pathways 2.2.3 Lack of Differentiation 2.2.4 Increased Angiogenesis 2.2.5 Potential for Metastasis 2.2.6 Genetic Instability 2.3 What Causes Cancer? 2.4 Worldwide Prevalence of Cancer: A Global Picture 2.5 What is Prostate Cancer? 2.6 Worldwide Prevalence of Prostate Cancer: Rapid Global Growth 2.7 Risk Factors in Prostate Cancer 2.8 How is Prostate Cancer Diagnosed? 2.8.1 PSA Testing 2.8.2 Digital Rectal Examination Testing 2.8.3 Prostate Cancer Screening: Does The Cost Justify The Means? 2.8.4 Alternative Tests Could Change Diagnostics 2.9 Treating Prostate Cancer 2.9.1 Localised Prostate Cancer: Surgery/Radiation is Most Preferred 2.9.1.1 Brachytherapy 2.9.1.2 Radical Prostatectomy 2.9.1.3 External Beam Radiation Therapy 2.9.1.4 Cryotherapy 2.9.1.5 High-Intensity Focussed Ultrasound (HIFU) 2.9.2 Advanced Local or Metastatic Prostate Cancer: Androgen Deprivation Therapy 2.9.3 Non-Metastatic CRPC: Ketoconazole and Anti-Androgens 2.9.4 Metastatic CRPC: Expanding the Standard Taxotere Treatment Paradigm 2.9.5 First Line Chemotherapy: Docetaxel is a Standard Treatment 2.9.6 Post Docetaxel Therapy: Five FDA Approved Drugs 2.9.7 Second Line Chemotherapy: Jevtana Approved in 2010
3. The Prostate Cancer Therapeutics Market 2015-2025 3.1 The Global Prostate Cancer Therapeutics Market, 2014 3.2 The Global Prostate Cancer Therapeutics Market Forecast, 2015-2025 3.3 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints, 2015-2025
4. The Prostate Cancer Drugs Market 2015-2025 4.1 The Prostate Cancer Drugs Market: Increasing Choice of Drugs will Mean Higher Competition 4.2 The Prostate Cancer Drugs Market, 2014 4.3 Leading Prostate Cancer Drugs: Market Forecast, 2015-2025 4.3.1 The Market Shares of Leading Prostate Cancer Drugs, 2015-2025 4.4 First Generation Chemotherapies 4.4.1 Taxotere (Sanofi) 4.4.1.1 Taxotere Sales, 2014 4.4.1.2 Taxotere Sales Forecast, 2015-2025 4.5 Second Generation Chemotherapies 4.5.1 Jevtana (Sanofi) 4.5.1.1 Jevtana Sales, 2014 4.5.1.2 Jevtana Sales Forecast, 2015-2025 4.6 First Generation Hormones 4.6.1 Casodex (AstraZeneca) 4.6.1.1 Casodex Sales, 2014 4.6.1.2 Casodex Sales Forecast, 2015-2025 4.6.2 Lupron (AbbVie) 4.6.2.1 Lupron Sales, 2014 4.6.2.2 Lupron Sales Forecast, 2015-2025 4.6.3 Zoladex (AstraZeneca) 4.6.3.1 Zoladex Sales, 2014 4.6.3.2 Zoladex Sales Forecast, 2015-2025 4.7 Second Generation Hormones 4.7.1 Zytiga (Johnson & Johnson) 4.7.1.1 Zytiga Sales, 2014 4.7.1.2 Zytiga Sales Forecast, 2015-2025 4.7.2 Xtandi (Medivation/ Astellas Pharma) 4.7.2.1 Xtandi Sales, 2014 4.7.2.2 Xtandi Sales Forecast, 2015-2025 4.8 Immunotherapies 4.8.1 Provenge (Dendreon Corporation) 4.8.1.1 Provenge Sales, 2014 4.8.1.2 Provenge Sales Forecasts, 2015-2025 4.9 Radiopharmaceuticals 4.9.1 Xofigo (Bayer) 4.9.1.1 Xofigo Sales, 2014 4.9.1.2 Xofigo Sales Forecast, 2015-2025 4.10 Other Drugs 4.11 Prostate Cancer Drugs Pipeline, 2015 4.11.1 Phase III Development 4.11.1.1 DCVax-Prostate (NorthWest Biotherapeutics) 4.11.1.2 Tookad Soluble (Steba Biotech) 4.11.1.3 ProstAtak (Advantagene) 4.11.1.4 ARN-509 (Johnson & Johnson) 4.11.1.5 Custirsen (Oncogenex) 4.11.1.6 Prostvac (Bavarian Nordic) 4.11.2 Failed Phase III Drugs 4.11.2.1 Cabozantinib (Elexis) 4.11.2.2 Yervoy (Bristol Myers Squibb) 4.11.2.3 Tasquinimod (Active biotech AB/Ipsen) 4.11.2.4 Orteronel (Millenium Pharmaceuticals) 4.11.3 Phase II development 4.11.3.1 GDC-0980 (Roche) 4.11.3.2 GDC-0068 (Roche) 4.11.3.3 PSMA ADC (Progenics Pharmaceuticals) 4.11.3.4 Galeterone (Tokai Pharmaceuticals) 4.11.3.5 OGX-427 (OncoGenex Pharmaceuticals) 4.11.3.6 Abituzumab (Dl7E6) (Merck) 4.11.4 Phase I 4.11.4.1 ASG-5ME (Agensys/Seattle Genetics) 4.11.4.2 EMD-525797 (EMD Serono) 4.11.4.3 MGAH22 (MacroGenics) 4.11.4.4 RG7450 (Roche) 4.11.4.5 BAY2010112 (Bayer Pharmaceuticals) 4.11.4.6 BX-201 (Bellicum Pharmaceuticals) 4.12 The Leading Companies in the Prostate Cancer Drugs Market, 2015 4.12.1 Johnson & Johnson 4.12.1.1 Sales and Performance Analysis, 2014 4.12.1.2 Pharmaceutical Segment Sales Analysis, 2014 4.12.1.3 Oncology Drugs Sales and Performance Analysis, 2014 4.12.1.4 Pharmaceutical Segment R&D Performance Analysis, 2014 4.12.1.5. Acquisition of Aragon Pharmaceuticals 4.12.2 AstraZeneca 4.12.2.1 Sales and Performance Analysis, 2014 4.12.2.2 Pharmaceutical Segment Sales & R&D Analysis by Segment, 2014 4.12.2.3 Oncology Drugs Sales and Performance Analysis, 2014 4.12.2.4 AstraZeneca Collaborates To Enhance Its Oncology Pipeline, 2014 4.12.3 Sanofi 4.12.3.1 Sales and Performance Analysis, 2014 4.12.3.2 Sales and Performance Analysis by Segment, 2014 4.12.3.3 Oncology Sales and Performance Analysis, 2014 4.12.3.4 R&D Performance Analysis, 2014 4.12.3.5 Oncology Pipeline Portfolio 4.12.4 AbbVie 4.12.4.1 Sales and Performance Analysis, 2014 4.12.4.2 R&D Performance Analysis, 2014 4.12.4.3 Humira: From “Firs-In-Class” to “Best-In-Class”, 2014 4.12.4.4 Oncology Portfolio Pipeline Products, 2014
5. The Prostate Cancer Devices Market 2015-2025 5.1 The Prostate Cancer Devices Market 2014 5.2 The Prostate Cancer Devices Market Forecast, 2015-2025 5.2.1 The Market Shares of Leading Prostate Cancer Devices Submarkets, 2015-2025 5.3 The Brachytherapy Market 2015-2025 5.4 The Radical Prostatectomy Market 2015-2025 5.4.1 Intuitive Surgical’s da Vinci Surgical System 5.5 The External Beam Radiation Therapy Market, 2015-2025 5.6 The HIFU Market, 2015-2025 5.7 The Cryotherapy Market, 2015-2025 5.8 Leading Companies in the Prostate Cancer Devices Market 2015-2025 5.8.1 Varian Medical Systems 5.8.1.1 Sales and Performance Analysis, 2014 5.8.1.2 Oncology Segment Sales Analysis, 2014 5.8.1.3 Sales Analysis by Region, 2014 5.8.1.4 R&D Performance Analysis, 2014 5.8.1.5 Key Oncology Products, 2014 5.8.1.6 Varian and Siemens Partnership: Shaping the Future of Cancer Care 5.8.2 Elekta 5.8.2.1 Sales and Performance Analysis, 2014 5.8.2.2 Sales and Performance Analysis by Region, 2014 5.8.2.3 Elekta and Philips Establish Research Consortium 5.8.2.4 Product Launch and Development, 2014 5.8.3 Theragenics Corporation (acquired by Juniper) 5.8.3.1 Theragenics Sales Performance Analysis, 2014 5.8.3.2 Theragenics Sales Performance by Operation, 2012 5.8.3.3 Sales and Performance Analysis by Business Unit, 2012 5.8.3.4 Mergers and Acquisitions 5.8.3.4.1 Juniper’s acquisition of Theragenics 5.8.3.4.2 Acquisition of Needle Tech Products 5.8.3.4.3 Acquisition of Galt Medical 5.8.3.4.4 Acquisition of CP Medical
6. The Leading National Markets 2015-2025 6.1 Regional Breakdown of the Prostate Cancer Therapeutics Market, 2014 6.2 The Prostate Cancer Therapeutics Market: Regional Forecast, 2015-2025 6.2.1 Market Shares Forecasts of Leading National Prostate Cancer Therapeutics Markets, 2015-2025 6.3 The US Prostate Cancer Therapeutics Market 2015-2025: Largest National Market 6.4 The European Prostate Cancer Therapeutics Market, 2014 6.4.1 The European Prostate Cancer Therapeutics Market, 2015-2025 6.4.1.1 The German Prostate Cancer Therapeutics Market, 2015-2025 6.4.1.2 The French Prostate Cancer Therapeutics Market, 2015-2025 6.4.1.3 The UK Prostate Cancer Therapeutics Market, 2015-2025 6.4.1.4 The Spanish Prostate Cancer Therapeutics Market, 2015-2025 6.4.1.5 The Italian Prostate Cancer Therapeutics Market, 2015-2025 6.5 The Japanese Prostate Cancer Therapeutics Market, 2015-2025 6.6 The Brazilian Prostate Cancer Therapeutics Market, 2015-2025 6.7 The Russian Prostate Cancer Therapeutics Market, 2015-2025 6.8 The Indian Prostate Cancer Therapeutics Market, 2015-2025 6.9 The Chinese Prostate Cancer Therapeutics Market, 2015-2025 6.10 The South Korean Prostate Cancer Therapeutics Market, 2015-2025 6.11 The Mexican Prostate Cancer Therapeutics Market, 2015-2025 6.12 The Rest of the World Prostate Cancer Therapeutics Market, 2015-2025
7. Qualitative Analysis of the Prostate Cancer Therapeutics Market 2015-2025 7.1 SWOT Analysis, 2015-2025 7.2 Strengths 7.2.1 Rapidly Expanding Ageing Population 7.2.2 A Number of Promising Drug Candidates 7.2.3 Successful Launches through Partnerships between Small/Big Pharma Companies 7.3 Weaknesses 7.3.1 Prostate Cancer Treatment is Expensive 7.3.2 The Chances of Failure Are Big 7.3.3 U.S Medical Excise Tax 7.4 Opportunities 7.4.1 Rising incidence of Cancer 7.4.2 Emerging Markets are Developing 7.5 Threats 7.5.1 Concerns about Efficacy and Toxicity of Drugs 7.5.2 Governments Decreasing Healthcare Spending 7.5.3 Increase in Generic Competition 7.6 Porter’s Five Force Analysis 7.6.1 Rivalry Among Competitors [High] 7.6.2 Threat of New Entrants [High] 7.6.3 Power of Suppliers [Low] 7.6.4 Power of Buyers [High] 7.6.5 Threat of Substitutes [Low]
8. Expert Opinion 8.1 Dr Katarzyna Nej-Wolosiak, Medical Science Lead, SOTIO 8.1.1 Issues in Prostate Cancer Treatment 8.1.2 Has Radical Prostatectomy Been Replaced? 8.1.3 Is Immunotherapy Still a Viable Option? 8.1.4 Current Challenges in Immunotherapy & Clinical Trial Design 8.1.5 Cost-effectiveness: Surgery vs Medical Treatments 8.1.6 How Cost-effective Is Immunotherapy? 8.1.7 DCVAC/ PCa: Mechanism of Action 8.1.8 DCVAC/ PCa: Side Effects & Immunotherapy 8.1.9 Advantages That Immunotherapy Offers 8.1.10 The Future of Immunotherapy: Shaping The Next Decade
9. Research Interviews 9.1 The Prostate Cancer Therapeutics Market, 2015-2025 9.2 The US Will Remain the Largest National Market from 2015 to 2025 9.3 Concluding Remarks
List of Tables Table 2.1 PSA Testing: Benefits and Limitations, 2015 Table 2.2 New Prostate Cancer Diagnostic Tests in Market, 2015 Table 2.3 Advantages and Disadvantages of Brachytherapy, 2015 Table 2.4 Advantages and Disadvantages of Radical Prostatectomy, 2015 Table 2.5 Advantages and Disadvantages of External Beam Radiation, 2015 Table 2.6 Advantages and Disadvantages of Cryotherapy, 2015 Table 2.7 Advantages and Disadvantages of HIFU, 2015 Table 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($m) and Market Share (%) by Segment, 2014 Table 3.2 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 3.3 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2015-2025 Table 4.1 The Prostate Cancer Drugs List: Key Brands, 2014 Table 4.2 The Prostate Cancer Drugs Market: Revenue ($m), Market Share (%) by Leading Drugs, 2014 Table 4.3 The Prostate Cancer Drugs Market Forecast by Leading Drugs, Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 4.4 Market Shares (%) of the Leading Prostate Cancer Drugs, 2019 and 2025 Table 4.5 Sanofi: Taxotere Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2025 Table 4.6 Sanofi: Jevtana Revenue Forecast ($m), AGR (%) and CAGR(%), 2014-2025 Table 4.7 AstraZeneca: Casodex Revenue Forecast ($m), AGR (%) and CAGR(%), 2014-2025 Table 4.8 AbbVie: Lupron Revenue Forecast ($m), AGR (%) and CAGR(%), 2014-2025 Table 4.9 Zoladex (AstraZeneca): Zoladex Revenue Forecast ($m), AGR (%) and CAGR(%), 2014-2025 Table 4.10 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%), CAGR(%), 2014-2025 Table 4.11 Medivation/Astellas: Xtandi Revenue Forecast ($m), AGR (%), CAGR(%), 2014-2025 Table 4.12 Provenge (Dendreon): Provenge Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2025 Table 4.13 Bayer: Xofigo Revenue Forecast ($m), AGR (%) and CAGR(%), 2014-2025 Table 4.14 Other Prostate Cancer Drugs: Revenue Forecast ($m), AGR (%) and CAGR(%), 2014-2025 Table 4.15 Key Drugs in Phase III Clinical Trials , 2015 Table 4.16 Negative Phase III Clinical Trials , 2015 Table 4.17 Key Drugs in Phase II Clinical Trials , 2015 Table 4.18 Key Drugs in Phase I Clinical Trials , 2015 Table 4.19 Johnson & Johnson: Revenue Shares (%) by Segment, 2014 Table 4.20 Johnson & Johnson: Historical Revenue ($bn), AGR (%) and CAGR (%), 2009-2014 Table 4.21 Johnson & Johnson Pharmaceuticals: Revenue ($bn), and Revenue Shares (%) by Segment, 2014 Table 4.22 Johnson & Johnson Pharmaceuticals: Top 5 Best Selling Drugs, 2014 Table 4.23 Johnson & Johnson: Oncology Pharmaceuticals Segment: Revenue ($m) by Drug, 2013-2014 Table 4.24 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Company Revenue (%), 2011-2014 Table 4.25 AstraZeneca: Revenue ($bn), AGR (%), 2011-2014 Table 4.26 AstraZeneca: Revenue ($bn), Revenue Shares (%) by Segment, 2014 Table 4.27 AstraZeneca: R&D costs and percentage of sales, 2011-2014 Table 4.28 AstraZeneca: Oncology Drugs Revenue ($m), 2012-2014 Table 4.29 AstraZeneca Oncology: Investigational compounds, 2014 Table 4.30 Sanofi: Revenue ($bn), AGR (%) and CAGR (%), 2010-2014 Table 4.31 Sanofi: Global Sales Revenue ($bn) and Percentage Change (%) by Region, 2013-2014 Table 4.32 Sanofi: Sale Revenue ($bn) and Revenue Shares (%) by Segment, 2014 Table 4.33 Sanofi: Revenue ($m) and Revenue Share (%) by Sub-Segments, 2014 Table 4.34 Sanofi: Oncology Sales ($m) by Product, 2013-2014 Table 4.35 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2010-2014 Table 4.36 AbbVie: Revenue ($bn), AGR (%) and CAGR (%), 2011-2014 Table 4.37 AbbVie Main Products: Revenue ($m) and Percentage Changes (%) from 2013 and 2014 Table 4.38 AbbVie: Humira Indications by Regions, 2014 Table 5.1 The Prostate Cancer Devices Market: Revenue ($m), Market Share (%) by Segment, 2014 Table 5.2 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Segment, 2014-2025 Table 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m) and Market Shares (%), 2014, 2019,2025 Table 5.4 The Brachytherapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 5.5 The Radical Prostatectomy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 5.6 The External Beam Radiation Therapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 5.7 The HIFU Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2025 Table 5.8 The Cryotherapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2025 Table 5.9 Varian Medical Systems: Revenue ($bn), AGR (%) and CAGR (%), 2010-2014 Table 5.10 Varian Medical Systems: Revenue ($bn) and Market Share (%), 2014 Table 5.11 Varian Medical Systems: Oncology Systems Revenue ($bn), Revenue Shares (%) by Segment, 2014 Table 5.12 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as Percentage of Revenue (%), 2011-2014 Table 5.13 Elekta: Revenue ($bn), AGR (%) and CAGR (%) 2010-2014 Table 5.14 Theragenics: Revenue ($m), AGR (%) and CAGR (%) 2008-2012 Table 5.15 Theragenics: Revenue ($m) and Revenue Share (%) by Business Unit, 2012 Table 6.1 The Prostate Cancer Therapeutics Market: Revenue ($m) and Market Share (%) by Region, 2014 Table 6.2 The Leading Prostate Cancer Therapeutics National Market Forecasts: Revenue ($m), AGR (%), CAGR (%), 2014-2025 Table 6.3 Market Shares (%) of the Leading Prostate Cancer Therapeutics National Markets, 2014, 2019 and 2025 Table 6.4 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 6.5 The European Prostate Cancer Therapeutics Markets: Revenue ($m), Market Share (%) by Country/Region, 2014 Table 6.6 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR(%), 2014-2025 Table 6.7 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR(%), 2014-2025 Table 6.8 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR(%), 2014-2025 Table 6.9 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR(%), 2014-2025 Table 6.10 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025 Table 6.11 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR(%), 2014-2025 Table 6.12 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR(%), 2014-2025 Table 6.13 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR(%), 2014-2025 Table 6.14 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR(%), 2014-2025 Table 6.15 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR(%), 2014-2025 Table 6.16 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR(%), 2014-2025 Table 6.17 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR(%), 2014-2025 Table 6.18 The Mexican Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR(%), 2014-2025 Table 6.19 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR(%), 2014-2025 Table 7.1 SWOT Analysis of the Prostate Cancer Therapeutics Market, 2015-2025
List of Figures Figure 1.1 The Global Over 65 Population: Forecast (millions, AGR%), 2013-2024 Figure 1.2 Prostate Cancer Therapeutics: Overview of Submarkets and Segments Figure 2.1 Risk Factors Associated with Cancer Development Figure 2.2 Global Proportion (%) of Newly Diagnosed Cancer by Type (Excluding Non-Melanoma Skin Cancer), 2012 Figure 2.3 Risk Factors Associated with Prostate Cancer Development Figure 2.4 Number of New Prostate Cancer Cases in the US per 100,000, by Ethnicity, 2012 Figure 2.5 Treatment Sequence for Prostate Cancer, 2015 Figure 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($m) by Segment, 2014 Figure 3.2 The Global Prostate Cancer Therapeutics Market: Market Share (%) by Segment, 2014 Figure 3.3 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 4.1 The Prostate Cancer Drugs Market: Revenue ($m) by Leading Drugs, 2014 Figure 4.2 The Prostate Cancer Drugs Market: Market Share (%) by Leading Drugs, 2014 Figure 4.3 The Prostate Cancer Drugs Market Forecast, Revenue ($m), AGR (%), 2014-2025 Figure 4.4 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drug, 2019 Figure 4.5 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drug, 2025 Figure 4.6 Taxotere (Sanofi): Taxotere Revenue Forecast ($m) and AGR (%) 2014-2025 Figure 4.7 Sanofi: Jevtana Revenue Forecast ($m) and AGR (%) 2014-2025 Figure 4.8 AstraZeneca: Casodex Revenue Forecast ($m) and AGR (%),2014-2025 Figure 4.9 AbbVie: Lupron Revenue Forecast ($m) and AGR (%) 2014-2025 Figure 4.10 AstraZeneca: Zoladex Revenue Forecast ($m) and AGR (%) 2014-2025 Figure 4.11 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%),2014-2025 Figure 4.12 Medivation/Astellas: Xtandi Revenue Forecast ($m) and AGR (%), 2014-2025 Figure 4.13 Provenge (Dendreon): Provenge Revenue Forecast ($m) and AGR (%) 2014-2025 Figure 4.14 Bayer: Xofigo Revenue Forecast ($m) and AGR (%),2014-2025 Figure 4.15 Other Prostate Cancer Drugs: Revenue Forecast ($m) and AGR (%), 2014-2025 Figure 4.16 Johnson & Johnson: Revenue Shares (%) by Segment, 2014 Figure 4.17 Johnson & Johnson: Historical Revenue ($bn) and AGR (%), 2009-2014 Figure 4.18 Johnson & Johnson Pharmaceuticals: Revenue($bn) by Segment, 2014 Figure 4.19 Johnson & Johnson Pharmaceuticals: Revenue Shares (%) by Segment, 2014 Figure 4.20 Johnson & Johnson Pharmaceuticals: Revenue Shares (%) by Leading Drugs, 2014 Figure 4.21 Johnson & Johnson Oncology Pharmaceuticals Segment: Market Share (%) by Drug, 2014 Figure 4.22 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Company Revenue (%), 2011-2014 Figure 4.23 AstraZeneca: Revenue ($bn), AGR (%), 2011-2014 Figure 4.24 AstraZeneca: Revenue ($bn) by Segment, 2014 Figure 4.25 AstraZeneca: Revenue Shares (%) by Segment, 2014 Figure 4.26 Astra Zeneca Pharmaceutical Pipeline: CVMD Compounds Currently Being Studied Figure 4.27 AstraZeneca Pharmaceutical Pipeline: Infection, Neuroscience and Gastrointestinal Compounds Currently being Studied Figure 4.28 AstraZeneca Pharmaceutical Pipeline: Infection, Neuroscience and Gastrointestinal Compounds Currently being Studied Figure 4.29 AstraZeneca Performance: R&D costs ($bn) and Percentage of sales (%), 2011-2014 Figure 4.30 AstraZeneca: Oncology Drugs Revenue ($m), 2012-2014 Figure 4.31 AstraZeneca: Revenue share (%) of all oncology drugs, 2014 Figure 4.32 AstraZeneca: Collaborations, 2014 Figure 4.33 Sanofi: Historical Revenue ($bn) and AGR (%), 2010-2014 Figure 4.34 Sanofi: Global Sales Revenue ($bn) and Percentage Change (%) by Region, 2013-2014 Figure 4.35 Sanofi: Revenue ($m) by Segment, 2014 Figure 4.36 Sanofi: Revenue Share (%) by Segment, 2014 Figure 4.37 Sanofi: Pharmaceutical Sub-segment Revenue shares (%), 2014 Figure 4.38 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Net Sales (%), 2010-2014 Figure 4.39 Sanofi: Major Compounds from Sanofi’s Oncology Pipeline, 2014 Figure 4.40 AbbVie: Revenue ($bn) and AGR (%), 2011-2014 Figure 4.41 AbbVie Main Products: Revenue ($m) Comparison, 2012-2014 Figure 4.42 AbbVie: Revenue Share (%) by Drug, 2014 Figure 4.43 AbbVie: R&D Segments, 2014 Figure 5.1 Segmentation of the Prostate Cancer Devices Market, 2014 Figure 5.2 The Prostate Cancer Devices Market: Revenue ($m) by Segment, 2014 Figure 5.3 The Prostate Cancer Devices Market: Market Share (%) by Segment, 2014 Figure 5.4 The Prostate Cancer Devices Market Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 5.5 The Prostate Cancer Devices Market Segments: Revenue ($m) Forecast, 2014, 2019, 2025 Figure 5.6 The Prostate Cancer Devices Market: Market Shares (%) by Leading Devices Submarkets, 2019 Figure 5.7 The Prostate Cancer Devices Market: Market Shares (%) by Leading Devices Submarkets, 2025 Figure 5.8 The Brachytherapy Market Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 5.9 The Radical Prostatectomy Market Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 5.10 The External Beam Radiation Therapy Market Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 5.11 The HIFU Market Forecast: Revenue ($m) and AGR (%), 2015-2025 Figure 5.12 The Cryotherapy Market Forecast: Revenue ($m), AGR (%), 2015-2025 Figure 5.13 Varian Medical Systems: Revenue ($bn) and AGR(%), 2010-2014 Figure 5.14 Varian Medical Systems: Revenue ($m) by Segment, 2014 Figure 5.15 Varian Medical Systems: Revenue Share (%) by Segment, 2014 Figure 5.16 Varian Medical Systems: Oncology Systems Revenue ($bn) by Segment, 2014 Figure 5.17 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Segment, 2014 Figure 5.18 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Region, 2014 Figure 5.19 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as Percentage of Revenue (%), 2011-2014 Figure 5.20 Elekta: Historical Revenue ($bn) and AGR (%), 2010-2014 Figure 5.21 Elekta: Historical Revenue by Region ($m), 2013-2014 Figure 5.22 Theragenics: Revenue ($m) and AGR (%), 2008-2012 Figure 5.23 Theragenics: Revenue Share (%) by Operation, 2012 Figure 5.24 Theragenics: Revenue ($m) by Business Unit, 2012 Figure 5.25 Theragenics: Revenue Share (%) by Business Unit, 2012 Figure 6.1 The Prostate Cancer Therapeutics Market: Revenue ($m) by Region, 2014 Figure 6.2 The Prostate Cancer Therapeutics Market: Market Share (%) by Region, 2014 Figure 6.3 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2019 Figure 6.4 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2025 Figure 6.5 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 6.6 The European Prostate Cancer Therapeutics Markets: Revenue ($m) by Country/Region, 2014 Figure 6.7 The European Prostate Cancer Therapeutics Markets: Market Share (%) by Country/Region, 2014 Figure 6.8 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%),2014-2025 Figure 6.9 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 6.10 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR(%), 2014-2025 Figure 6.11 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%),2014-2025 Figure 6.12 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2025 Figure 6.13 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 6.14 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%),2014-2025 Figure 6.15 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%),2014-2025 Figure 6.16 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%),2014-2025 Figure 6.17 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%),2014-2025 Figure 6.18 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%),2014-2025 Figure 6.19 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 6.20 The Mexican Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 6.21 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%),2014-2025 Figure 7.1 Porter’s Five Force Analysis of the Prostate Cancer Therapeutics Market, 2015-2025
Other Organisations Mentioned in this Report American Cancer Society (ACS) American Society of Clinical Oncology (ASCO) American Society of Gene and Cellular Therapy (ASGCT) Brazilian Industrial Biotech Association Brigham Young University Carnegie Institution for Science Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia) European Medicines Agency (EMA) European Patent Office (EPO) Georgetown University Hannover Medical School Kunshan RNAi Institute Mary Crowley Cancer Research Centre Max Planck Institute MD Anderson Cancer Center Ministry of Science and Technology (India) National Institute for Health and Care Excellence (NICE) (UK) National Institutes of Health (NIH) (US) Ohio State University (OSU) Pachyonychia Congenita Project United States Food and Drug Administration (FDA) University of Bayreuth University of Calgary University of Helsinki University of Massachusetts Medical School University of Oxford University of Pittsburgh US Department of Defense Wellcome Trust World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for The Prostate Cancer Therapeutics Market Forecast 2015-2025
Download sample pages
Complete the form below to download your free sample pages for The Prostate Cancer Therapeutics Market Forecast 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.
Visiongain Publishes Antigen Skin Test Market Report to 2031
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships.
Visiongain Publishes Anti-Infective Vaccines Market Report Report to 2031
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.